JATT Acquisition (JATT) Competitors

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

$3.69

+0.56 (+17.89%)

(As of 04/18/2024 ET)

Stock Analysis Chart Competitors Financials SEC Filings Social Media

JATT vs. DYAI, CRTX, IKNA, QNCX, GNTA, ALGS, OKYO, TSBX, ESLA, and ENTX

Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Dyadic International (DYAI), Cortexyme (CRTX), Ikena Oncology (IKNA), Quince Therapeutics (QNCX), Genenta Science (GNTA), Aligos Therapeutics (ALGS), OKYO Pharma (OKYO), Turnstone Biologics (TSBX), Estrella Immunopharma (ESLA), and Entera Bio (ENTX). These companies are all part of the "medical" sector.

JATT Acquisition vs.

JATT Acquisition (NYSE:JATT) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.

: In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.
Company Overall Sentiment
JATT Acquisition Neutral
Dyadic International Neutral
: JATT Acquisition has higher earnings, but lower revenue than Dyadic International.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
JATT Acquisition N/A N/A $6.85M N/A N/A
Dyadic International $2.90M 15.88 -$6.80M -$0.24 -6.62
: 48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 27.3% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Dyadic International received 158 more outperform votes than JATT Acquisition when rated by MarketBeat users.
Company Underperform Outperform
JATT Acquisition N/A N/A
Dyadic International Outperform Votes
158
63.97%
Underperform Votes
89
36.03%
: Dyadic International has a consensus target price of $6.00, suggesting a potential upside of 277.36%. Given Dyadic International's higher possible upside, analysts clearly believe Dyadic International is more favorable than JATT Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JATT Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Dyadic International
0 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
3.00
: JATT Acquisition has a net margin of 0.00% compared to Dyadic International's net margin of -234.39%. JATT Acquisition's return on equity of -49.58% beat Dyadic International's return on equity.
Company Net Margins Return on Equity Return on Assets
JATT Acquisition N/A -49.58% 2.84%
Dyadic International -234.39% -81.57% -65.71%

Company	Overall Sentiment
JATT Acquisition	Neutral
Dyadic International	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Dyadic International	$2.90M	15.88	-$6.80M	-$0.24	-6.62

Company	Underperform	Outperform
JATT Acquisition	N/A	N/A
Dyadic International	Outperform Votes 158 63.97%	Underperform Votes 89 36.03%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Dyadic International	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Dyadic International	-234.39%	-81.57%	-65.71%

Summary

JATT Acquisition and Dyadic International tied by winning 5 of the 10 factors compared between the two stocks.

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

Get JATT Acquisition News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JATT vs. The Competition

Export to Excel

Metric	JATT Acquisition	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$63.65M	$2.61B	$4.79B	$17.14B
Dividend Yield	N/A	2.30%	2.98%	3.62%
P/E Ratio	N/A	21.33	191.64	21.33
Price / Sales	N/A	288.03	2,563.79	9.66
Price / Cash	27.08	143.31	46.87	16.92
Price / Book	-6.96	3.78	4.58	4.84
Net Income	$6.85M	-$44.84M	$103.64M	$969.88M
7 Day Performance	28.57%	-7.63%	-3.80%	-2.30%
1 Month Performance	19.81%	-9.27%	-5.31%	-3.08%
1 Year Performance	-62.69%	1.49%	7.35%	77.61%

JATT Acquisition Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	1.1864 of 5 stars	$1.80 +7.8%	$6.00 +233.3%	-3.0%	$52.15M	$2.90M	-7.50	7	Positive News
CRTX Cortexyme	0 of 5 stars	$1.01 +6.3%	N/A	-30.7%	$58.79M	N/A	-0.34	55
IKNA Ikena Oncology	1.8317 of 5 stars	$1.27 -0.8%	$9.50 +648.0%	-74.5%	$61.29M	$9.16M	-0.77	43
QNCX Quince Therapeutics	0 of 5 stars	$1.00 -1.0%	N/A	-30.7%	$43.07M	N/A	-1.19	21	High Trading Volume
GNTA Genenta Science	0 of 5 stars	$3.43 -0.3%	N/A	-41.3%	$62.54M	N/A	0.00	4	Upcoming Earnings Gap Up
ALGS Aligos Therapeutics	1.2699 of 5 stars	$0.84 -6.7%	N/A	-16.6%	$63.18M	$15.53M	-0.53	66
OKYO OKYO Pharma	1.589 of 5 stars	$1.43 +2.1%	$7.00 +389.5%	+14.8%	$41.23M	N/A	0.00	8	Gap Down
TSBX Turnstone Biologics	2.2133 of 5 stars	$2.80 -0.4%	$19.00 +578.6%	N/A	$64.68M	$19.31M	0.00	80	News Coverage Gap Up
ESLA Estrella Immunopharma	0 of 5 stars	$1.09 +1.9%	N/A	N/A	$39.72M	N/A	0.00	N/A
ENTX Entera Bio	1.7462 of 5 stars	$2.29 -9.1%	$10.00 +336.7%	+160.6%	$65.95M	$130,000.00	-7.39	17	Positive News High Trading Volume

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NYSE:JATT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

JATT Acquisition (JATT) Competitors

JATT vs. DYAI, CRTX, IKNA, QNCX, GNTA, ALGS, OKYO, TSBX, ESLA, and ENTX

JATT Acquisition vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info